CLINICAL_TRIALS
trial_result
· 2021-03-04
Clinical Trial Update: PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment [Phase 4]
Summary
Phase 4 trial update evaluating polymorphisms and incidence of toxicity in eribulin treatment for metastatic breast cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Oncologia Medica dell'Ospedale Fatebenefratelli | Conditions: Metastatic Breast Cancer, Toxicity | Phase 4 | Status: COMPLETED